Intercell company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Acq - P2P | Acquired

About Intercell

Intercell AG, (formerly Iomai Corp.) has developed a method to safely and more effectively deliver vaccines through the use of a skin patch and without any injections.

Intercell Headquarter Location

Campus Vienna Biocenter 6


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Intercell Patents

Intercell has filed 35 patents.

The 3 most popular patent topics include:

  • Acetylcholinesterase inhibitors
  • Bacterial toxins
  • Immunology
patents chart

Application Date

Grant Date


Related Topics




Acetylcholinesterase inhibitors, Organophosphate insecticides, Bacterial toxins, Immunology, Proteins


Application Date


Grant Date



Related Topics

Acetylcholinesterase inhibitors, Organophosphate insecticides, Bacterial toxins, Immunology, Proteins



Latest Intercell News

Sonu Sood backs post K-12 mentoring startup Intercell, comes on board as Co-Founder

Nov 19, 2021

A+ New Delhi [India], November 19 (ANI/Mediawire): Youth icon Sonu Sood and Post K-12 Mentoring startupIntercell have announced a strategic alliance to assist the youth by providing seamless and affordable career mentoring services through technology solutions. The collaboration aims to provide career advice and direction to new Graduates and Young Professionals through mentoring by leading Industry professionals across the world. Post pandemic, there is a growing need to guide and assist career aspirants, especially in challenging times, amidst the plethora of opportunities available to them. Intercell solves the problem of finding the right mentors to guide students and professionals. Arunabh Varma, Founder and CEO Intercell, remarked, “We are extremely excited to partner with Sonu Sood to establish the category of Mentoring in India. He is a Youth Icon with a massive following and will help Intercell to position itself in both the B2C and B2B category. We aim to provide seamless Mentoring services to Graduates and Young Professionals. To uncover the secret of a successful career, our network of Global Mentors come to the aid of innumerable students and professionals across the globe.” Commenting on this partnership, Sonu Sood said, “It is very important to help Graduates and Young professionals succeed in their careers. With the help of technology now we will bring the best Mentors from the world to give Career Mentoring to our youth in India.” This story is provided by Mediawire. ANI will not be responsible in any way for the content of this article. (ANI/Mediawire) This story is auto-generated from a syndicated feed. ThePrint holds no responsibility for its content. Subscribe to our channels on YouTube & Telegram Why news media is in crisis & How you can fix it India needs free, fair, non-hyphenated and questioning journalism even more as it faces multiple crises. But the news media is in a crisis of its own. There have been brutal layoffs and pay-cuts. The best of journalism is shrinking, yielding to crude prime-time spectacle. ThePrint has the finest young reporters, columnists and editors working for it. Sustaining journalism of this quality needs smart and thinking people like you to pay for it. Whether you live in India or overseas, you can do it here .

  • What is Intercell's latest funding round?

    Intercell's latest funding round is Acq - P2P.

  • Who are the investors of Intercell?

    Investors of Intercell include Valneva, Thuja Capital Management, Global Life Science Ventures, Techno Ventures, MPM Capital and 4 more.

  • Who are Intercell's competitors?

    Competitors of Intercell include Aura Biosciences, Erydel, OptiNose, MediQuest Therapeutics, Cellnovo and 12 more.

You May Also Like


EryDel develops a red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient's own blood, which are then re-infused into the patient.

Global Protein Products

Global Protein Products (GPP) is a zein protein coatings company. Zein protein is the storage protein in corn kernels. It has excellent film-forming and thermoplastic characteristics.

Talima Therapeutics

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

MAD Nanolayers

MAD Nanolayers aims to provide a patented coating technology for delivering multiple agents sequentially and with precise control over dosage and timing. This is a platform technology with many therapeutic and non-therapeutic applications and whose disruptive feature is not available in any other coating technology today. MAD Nanolayers' primary offering will be a therapeutic coating for orthopedic implants that aims to deliver painkillers, antibiotics, and growth factors to minimize post-surgical complications and aims to eliminate subsequent re-intervention procedures, resulting in cost-savings to the hospitals and improved quality of life for patients.

Kucera Pharmaceutical Company

Kucera Pharmaceutical Company is based in Winston-Salem, NC. The company started with a drug delivery approach that combined or conjugated delivery molecules with therapeutic molecules as a platform technology, both to improve the properties of the attached therapeutic molecules (making them orally available and improving distribution) and to extend patent life.

Nano Discovery

Nano Discovery aims to provide customer-designed synthesis and development of a range of nanomaterials including nanoparticles, quantum dots, polymers, conjugated conducting polymers, nanofibers, nanotubes, nanoporous particles, colloidal particles (liposomes and vesicles), monolayer and multilayer thin films, and nanocomposite materials. Applications of the materials include biomolecular imaging, bioassay, drug delivery, cancer therapy, electronic materials, coatings and packaging for electronic devices, coatings for corrosion protection, conformable batteries, supercapcitors, and photovoltaic cells. The company also have developed or licensed some signature nanomaterial products which can be made-to-order for the company's customers.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.